Publications by authors named "Mohamad El Kasty"
Article Synopsis
- Seizures can cause serious complications like cardiac problems and Takotsubo syndrome, which is a heart condition triggered by stress that resembles a heart attack.
- A case study of a 66-year-old woman with epilepsy showed that a prolonged seizure led to heart issues, including elevated troponin levels and heart function problems, with normal coronary arteries.
- After receiving adjusted anti-seizure treatments and cardiac care in the ICU, the patient improved significantly, underlining the need for coordinated care between neurology and cardiology to address these complications.
Background: The appropriate duration of treatment with beta-blocker drugs after a myocardial infarction is unknown. Data are needed on the safety and efficacy of the interruption of long-term beta-blocker treatment to reduce side effects and improve quality of life in patients with a history of uncomplicated myocardial infarction.
Methods: In a multicenter, open label, randomized, noninferiority trial conducted at 49 sites in France, we randomly assigned patients with a history of myocardial infarction, in a 1:1 ratio, to interruption or continuation of beta-blocker treatment.
Article Synopsis
- The study aimed to analyze whether ticagrelor is more effective than clopidogrel in reducing heart damage during elective coronary procedures for patients with and without prior clopidogrel treatment.
- Out of 1,882 participants, those who were not on clopidogrel had a lower rate of heart injury compared to those who had been, but overall, ticagrelor did not show significant benefits over clopidogrel for reducing complications.
- The findings suggest that clopidogrel-naive patients generally experienced fewer complications due to a lower risk profile and simpler procedures, with no notable differences in outcomes based on previously taking clopidogrel.
Article Synopsis
- The study aimed to assess the effectiveness of ticagrelor versus clopidogrel in preventing cardiovascular events among chronic coronary syndrome patients undergoing complex percutaneous coronary interventions (PCI).
- Among 1,866 patients in the trial, nearly half were identified as having complex PCI, which was associated with significantly higher rates of myocardial infarction and other complications.
- Despite the increased risk associated with complex PCI, ticagrelor did not demonstrate any advantage over clopidogrel in reducing these adverse events.
Article Synopsis
- The study aimed to investigate the effects of the timing of P2Y inhibitor administration on myocardial necrosis during elective percutaneous coronary intervention (PCI), utilizing data from the ALPHEUS trial.
- Results revealed that patients who received P2Y inhibitors closer to the PCI procedure had higher rates of myocardial necrosis compared to those who were given the medication earlier, with improved outcomes seen in groups that received longer loading times.
- While the study found a correlation between timing and myocardial injury, it noted that bleeding complications were minimal and did not vary significantly among the different timing groups, leaving long-term clinical effects unclear.
Aims: The respective roles of oral anticoagulation or antiplatelet therapy following transcatheter aortic valve implantation (TAVI) remain debated. ATLANTIS is an international, randomized, open-label, superiority trial comparing apixaban to the standard of care.
Methods And Results: After successful TAVI, 1500 patients were randomized (1:1) to receive apixaban 5 mg (2.
Article Synopsis
- The ALPHEUS study aimed to determine if ticagrelor is more effective than clopidogrel in reducing heart muscle injury during elective PCI in stable coronary patients.
- Conducted across 49 hospitals in France and the Czech Republic, it involved 1910 participants who were randomly assigned to receive either ticagrelor or clopidogrel before the procedure.
- Results showed no significant difference in the primary endpoint of myocardial injury between the two groups, with about 35% in the ticagrelor group and 36% in the clopidogrel group affected, indicating ticagrelor did not outperform clopidogrel in this context.
Article Synopsis
- Clopidogrel combined with aspirin is the standard treatment for patients undergoing elective PCI, but complications like myocardial infarction can occur.
- Evidence supports the potential benefits of using ticagrelor, a type of P2Y receptor inhibitor, which may help reduce ischemic complications while maintaining a similar safety profile to clopidogrel.
- The ALPHEUS trial will compare the effects of ticagrelor and clopidogrel on patients undergoing elective PCI, focusing on reducing myocardial injury and evaluating major bleeding risks.